These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30116245)

  • 1. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
    Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
    Front Immunol; 2018; 9():1758. PubMed ID: 30116245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
    Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
    J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exhaustion of the CD8
    Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
    Front Immunol; 2018; 9():446. PubMed ID: 29563914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
    Cohen JI
    Front Immunol; 2018; 9():237. PubMed ID: 29599765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
    Condliffe AM; Chandra A
    Front Immunol; 2018; 9():338. PubMed ID: 29556229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
    Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
    J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
    Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
    J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
    Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
    Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Challenges: Identification of Patients With Novel Primary Immunodeficiency Syndromes.
    Buchbinder D; Seppanen M; Rao VK; Uzel G; Nugent D
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e319-e322. PubMed ID: 29200144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
    Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
    Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
    [No Abstract]   [Full Text] [Related]  

  • 11. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
    Carpier JM; Lucas CL
    Front Immunol; 2017; 8():2005. PubMed ID: 29387064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency.
    Lucas CL; Kuehn HS; Zhao F; Niemela JE; Deenick EK; Palendira U; Avery DT; Moens L; Cannons JL; Biancalana M; Stoddard J; Ouyang W; Frucht DM; Rao VK; Atkinson TP; Agharahimi A; Hussey AA; Folio LR; Olivier KN; Fleisher TA; Pittaluga S; Holland SM; Cohen JI; Oliveira JB; Tangye SG; Schwartzberg PL; Lenardo MJ; Uzel G
    Nat Immunol; 2014 Jan; 15(1):88-97. PubMed ID: 24165795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
    Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
    Front Immunol; 2018; 9():568. PubMed ID: 29675019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.
    Lucas CL; Zhang Y; Venida A; Wang Y; Hughes J; McElwee J; Butrick M; Matthews H; Price S; Biancalana M; Wang X; Richards M; Pozos T; Barlan I; Ozen A; Rao VK; Su HC; Lenardo MJ
    J Exp Med; 2014 Dec; 211(13):2537-47. PubMed ID: 25488983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
    Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
    J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
    Liu H; Tang XL; Liu JR; Li HM; Zhao SY
    Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: A case report.
    Li GM; Liu HM; Guan WZ; Xu H; Wu BB; Feng JY; Sun L
    Medicine (Baltimore); 2019 May; 98(18):e15329. PubMed ID: 31045771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
    Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
    Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
    Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.